Dr. Wang is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
333 Cottman Avenue
W364
Philadelphia, PA 19111Phone+1 215-728-3064
Summary
- Dr. Y. Lynn Wang, a board-certified molecular pathologist, is specialized in the development and interpretation of molecular and genomic clinical assays including PCR, RT-PCR, FISH, Sanger sequencing and Next-gen sequencing assays. She served as the Founding Director of the Genomic and Molecular Pathology Division at the University of Chicago and Director of Molecular Hematopathology at Weill Cornell Medical College before she joined Fox Chase Cancer Center in 2018. She contributed >75 publications to the medical and scientific literature. Many of them are well cited including the report in the New England Journal of Medicine and two top-cited articles in Leukemia. Dr. Wang is an inventor on two issued US patents.
Education & Training
- University of Pennsylvania Health SystemResidency, Pathology-Anatomic and Clinical, 1998 - 2002
- University of Pennsylvania Health SystemFellowship, Molecular Genetic Pathology, 1995 - 1997
- Brandeis UniversityPh.D., Molecular Biology/Biochemistry, 1995
- Beijing Medical UniversityClass of 1988
Certifications & Licensure
- PA State Medical License 2019 - 2024
- IL State Medical License 2013 - 2023
- NY State Medical License 2002 - 2022
- MI State Medical License 2000 - 2007
- American Board of Pathology Clinical Pathology
- American Board of Pathology Pathology - Molecular Genetic
Awards, Honors, & Recognition
- Medical Consultant Asuragen, 2017
- Yao Yuan Award for Research Excellence 2017
- Article entitled “Functional characterization of BTKC481S mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors” is ranked as one of most highly cited papers published in Leukemia from 2015 2017
- Join now to see all
Publications & Presentations
PubMed
- 2 citationsSHP1 loss augments DLBCL cellular response to ibrutinib: a candidate predictive biomarker.Wenjun Wu, Pin Lu, Priyal Patel, Ji Ma, Kathy Qi Cai
Oncogene. 2023-02-01 - Cardiovascular Involvement of a CD138-Negative Anaplastic Myeloma: A Diagnostic Dilemma.Jui Choudhuri, Victor Janmey, Juan Ding, Denise Dailey, Yang Shi
Hematology Reports. 2023-01-18 - 38 citationsResistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non-Hodgkin lymphoma.Shazia Nakhoda, Aldana Vistarop, Y Lynn Wang
British Journal of Haematology. 2023-01-01
Journal Articles
- Cyclophilin A-regulated ubiquitination is critical for RIG-I-mediated antiviral immune responsesLiu W, Li J, Zheng W, Shang Y, Zhao Z, Wang S, Bi Y, Zhang S, Xu C, Duan Z, Zhang L, Wang YL, Jiang Z, Liu W, and Sun L, eLife, 1/1/2017
- Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLLKadri S, Lee J, Fitzpatrick C, Galanina N, Sukhanova M, Venkataraman G, Sharma S, Long B, Petras K, Theissen M, Ming M, Kobzev Y, Kang W, Guo A, Wang W, Niu N, Weiner ..., Blood Advances, 1/1/2017
- B-cell lymphoma patient-derived xenograft models enable drug discovery and are a platform for personalized therapyZhang L, Nomie K, Zhang H, Bell T, Pham L, Kadri S, Segal J, Li S, Zhou S, Santos D, Richard S, Sharma S, Chen W, Oriabure O, Liu Y, Huang S, Guo H, Chen Z, Tao W, Li ..., Clin Can Res, 1/1/2017
- Join now to see all
Books/Book Chapters
Lectures
- Inhibition of B-Cell Receptor Signaling Disrupts Cell Adhesion in Mantle Cell Lymphoma Via RAC22018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Ibrutinib resistance in CLL and exploration of alternative therapies1/2/2018
- Ibrutinib resistance and exploration of alternative therapies using a personalized CLL Rx modelChicago, IL - 1/26/2017
- Join now to see all
Other
- New challenges and personalized therapies in CLLGalanina N, Wang YL and Smith SM, Frontline, Lymphoma Research Foundation Newsletter
1/1/2015 - Interviewed and featured in Oncology.TV on “Evaluating Cerdulatinib in Diffuse large B Cell Lymphoma”
http://oncology.tv/OncologyTVNetwork/TabId/1455/VideoId/1541/Dr-Lynn-Wang-Discusses-Evaluating-Cerdulatinib-In-Diffuse-Large-B-Cell-Lymphoma.aspx
1/1/2015 - NCI Cancer Center News: Tiny mutation triggers drug resistance for patients with one type of leukemia
1/1/2014 - Join now to see all
Professional Memberships
- Member
External Links
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: